Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity - Archive ouverte HAL Access content directly
Journal Articles Nature Communications Year : 2022

Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity

(1) , (1) , (1) , (2) , (2, 3) , (4) , (5) , (1, 6) , (4) , (1) , (1) , (7) , (8, 9) , (8, 9) , (10, 11, 12) , (10, 11, 12, 13) , (14) , (14) , (3, 2) , (2) , (2, 3) , (2) , (1, 4)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Jamie Sugrue
Liam Townsend
Vincent Rouilly
  • Function : Author
Olivier Schwartz
Benjamin Terrier
  • Function : Author

Abstract

Host immunity to infection with SARS-CoV-2 is highly variable, dictating diverse clinical outcomes ranging from asymptomatic to severe disease and death. We previously reported reduced type I interferon in severe COVID-19 patients preceded clinical worsening. Further studies identified genetic mutations in loci of the TLR3- or TLR7-dependent interferon-I pathways, or neutralizing interferon-I autoantibodies as risk factors for development of COVID-19 pneumonia. Here we show in patient cohorts with different severities of COVID-19, that baseline plasma interferon α measures differ according to the immunoassay used, timing of sampling, the interferon α subtype measured, and the presence of autoantibodies. We also show a consistently reduced induction of interferon-I proteins in hospitalized COVID-19 patients upon immune stimulation, that is not associated with detectable neutralizing autoantibodies against interferon α or interferon ω. Intracellular proteomic analysis shows increased monocyte numbers in hospitalized COVID-19 patients but impaired interferon-I response after stimulation. We confirm this by ex vivo whole blood stimulation with interferon-I which induces transcriptomic responses associated with inflammation in hospitalized COVID-19 patients, that is not seen in controls or non-hospitalized moderate cases. These results may explain the dichotomy of the poor clinical response to interferon-I based treatments in late stage COVID-19, despite the importance of interferon-I in early acute infection and may guide alternative therapeutic strategies.
Fichier principal
Vignette du fichier
s41467-022-34895-1.pdf (2.47 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

pasteur-03884236 , version 1 (05-12-2022)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Nikaïa Smith, Céline Possémé, Vincent Bondet, Jamie Sugrue, Liam Townsend, et al.. Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. Nature Communications, 2022, 13 (1), pp.7254. ⟨10.1038/s41467-022-34895-1⟩. ⟨pasteur-03884236⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More